培门冬酶注射液致急性重症胰腺炎1例分析

doi:10.19803/j.1672-8629.20240313

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (9): 1075-1077.
DOI: 10.19803/j.1672-8629.20240313

培门冬酶注射液致急性重症胰腺炎1例分析

刘婷¹, 曹忠强¹, 何文佳¹, 袁秀丽², 陈泽彬¹, 李学娟^1,*

¹深圳市儿童医院药剂科,广东深圳 518038;
²深圳市儿童医院血液肿瘤科,广东深圳 518038

收稿日期:2024-05-11 出版日期:2024-09-15 发布日期:2024-09-14
通讯作者: ^*李学娟,女,硕士,主任药师,临床药学。E-mail: xuejuanli@126.com
作者简介:刘婷,女,硕士,主管药师,临床药学。
基金资助:
广东省高水平医院建设专项经费资助（ynkt2022-zz23）

One case of acute severe pancreatitis caused by pegaspargase and its etiology

LIU Ting¹, CAO Zhongqiang¹, HE Wenjia¹, YUAN Xiuli², CHEN Zebin¹, LI Xuejuan^1,*

¹Department of Pharmacy, Shenzhen Children's Hospital, Shenzhen Guangdong 518038, China;
²Department of Hematologic Oncology, Shenzhen Children's Hospital, Shenzhen Guangdong 518038, China

Received:2024-05-11 Online:2024-09-15 Published:2024-09-14

摘要/Abstract

摘要： 目的探讨培门冬酶引起急性重症胰腺炎的临床特点及可能影响因素,为肿瘤患儿临床用药提供参考。方法分析1例T淋巴母细胞淋巴瘤患儿培门冬酶治疗后出现急性胰腺炎病例,经停药、禁食、予对症处理后恢复,评估后再次予培门冬酶治疗后再现急性胰腺炎。采用Naranjo评分并结合文献资料,分析诱发胰腺炎的危险因素。结果根据患儿的临床表现及用药时间关联性,结合Naranjo评分9分,确定培门冬酶为引起急性胰腺炎的药物,同时高脂饮食可能是急性胰腺炎的诱因。结论培门冬酶可致急性胰腺炎,治疗期间应强调低脂饮食,医护人员应加强对该药相关胰腺炎的防治认识。

关键词: 培门冬酶, 注射液, 急性胰腺炎, 药品不良反应, T淋巴母细胞淋巴瘤, 儿童, 安全性

Abstract: Objective To explore the clinical characteristics and potential risk factors of severe acute pancreatitis caused by pegaspargase and caution clinicians against the adverse effect of this drug. Methods The clinical data of one child with T lymphoblastic lymphoma who developed acute severe pancreatitis after medication with pegaspargase was studied. After withdrawal of pegaspargase, fasting, and supplemental treatment, the patient's symptoms were significantly relieved. After evaluation and repeated use of pegaspargase, acute pancreatitis reoccurred but improved as result of symptomatic treatment. The risk factors for pancreatitis were analyzed based on the Naranjo score and literature review. Results Based on the manifestations of acute pancreatitis, the relationship with the timing of medication, and a Naranjo score of 9, pegaspargase was confirmed as the cause of acute pancreatitis, and a high-fat diet might be a risk factor. Conclusion Clinicians should advance their understanding of and be alert to acute pancreatitis associated with pegaspargase. Low-fat diet should be recommended during treatment.

Key words: pegaspargase, injection, acute pancreatitis, adverse drug reactions, T-lymphoblastic lymphoma, children, saftey

中图分类号:

刘婷, 曹忠强, 何文佳, 袁秀丽, 陈泽彬, 李学娟. 培门冬酶注射液致急性重症胰腺炎1例分析[J]. 中国药物警戒, 2024, 21(9): 1075-1077.

LIU Ting, CAO Zhongqiang, HE Wenjia, YUAN Xiuli, CHEN Zebin, LI Xuejuan. One case of acute severe pancreatitis caused by pegaspargase and its etiology[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1075-1077.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240313

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I9/1075

参考文献

[1] BADALOV N, BARADARIAN R, ISWARA K, et al.Drug-induced acute pancreatitis: an evidence-based review[J]. Clinical Gastroenterology & Hepatology, 2007, 5(6): 648-661.
[2] SHI XD, LUO D, LIU Y, et al.Acute necrotizing pancreatitis in children with T lymphoblastic lymphoma caused by pegaspargase: a case report[J]. Journal of Pediatric Pharmacy(儿科药学杂志), 2023, 29(5): 65-66.
[3] CHEN ZS, LI J.Experience in diagnosis and treatment of asparaginase-associated pancreatitis in children[J]. Chinese Journal of Pediatrics(中华儿科杂志), 2014, 52(11): 854-858.
[4] Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association. Guidelines for diagnosis and treatment of acute pancreatitis in China (2021)[J]. Chinese Journal of Surgery(中华外科杂志), 2021, 59(7): 10.
[5] BOXHOORN L, VOERMANS RP, BOUWENSE SA, et al.Acute pancreatitis[J]. Lancet, 2020, 396(10252): 726-734.
[6] National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE)Version 5[J/OL]. (2017-11-27)[2024-05-10]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
[7] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clinical Pharmacology and Therapeutics, 1981, 30(2): 239-245.
[8] SAINI J, MARINO D, BADALOV N, et al.Drug-induced acute pancreatitis: an evidence-based classification (revised)[J]. Clinical Translational Gastroenterology, 2023, 14(8): e00621.
[9] M’HARZI S, ELOUALI A, LAHRACHE K, et al. Acute pancreatitis following l-asparaginase in acute lymphoblastic leukemia[J]. Leukemia Research Reports, 2022, 18: 100357.
[10] YU W, HU Q, LIU A, et al.Clinical characteristics of 31 children with acute lymphoblastic leukemia accompanied with acute pancreatitis treated with polyethylene glycol conjugated asparaginase[J]. Herald of Medicine(医药导报), 2022, 41(9): 1374-1377.
[11] KEARNEY SL, DAHLBERG SE, LEVY DE, et al.Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis[J]. Pediatric Blood & Cancer, 2009, 53(2):162-167.
[12] SKIPPER MT, ALBERTSEN BK, SCHMIEGELOW K, et al.Long-term effects of asparaginase-associated pancreatitis[J]. Pediatric Blood & Cancer, 2023, 70(9): e30528.
[13] OPARAJI JA, ROSE F, OKAFOR D, et al.Risk factors for asparaginase-associated pancreatitis a systematic review[J]. Journal of Clinical Gastroenterology, 2017, 51(10): 907-913.
[14] ZHANG N, WANG HL, ZHONG GZ, et al.Mining and evaluation of post-marketing safe alert signals of pegaspargase and L-asparaginase based on BCPNN method[J]. China Pharmacy(中国药房), 2021, 32(16): 2012-2018.
[15] ZHANG N.Safety, efficacy and economy of pegaspargase and L-aspargase in first treatment of acute lymphoblastic leukemia[D]. Chongqing: Chongqing Medical University, 2022.
[16] WEN D, XU X, ZHANG L.Comparison of therapeutic effects of l-aspargase and pegaspargase on children with acute lymphoblastic leukemia[J]. Chinese Journal of Woman and Child Health Research(中国妇幼健康研究), 2024, 35(4): 67-73.
[17] BUIE LW, MOORE J, DEVENTER HV.Successful use of octreotide as a chemo-protectant for prevention of PEG-asparaginase-induced pancreatitis[J]. Pharmacotherapy, 2014, 34(8): e149-e151.
[18] SAKAGUCHI S, HIGA T, SUZUKI M, et al.Prophylactic use of octreotide for asparaginase-induced acute pancreatitis[J]. International Journal Hematology, 2017, 106(2): 266-268.
[19] ZHENG Z, DING YX, QU YX, et al.A narrative review of the mechanism of acute pancreatitis and recent advances in its clinical management[J]. American Journal of Translational Research, 2021, 13(3): 833-852.
[20] OLAND GL, HINES OJ.New guidelines for the treatment of severe acute pancreatitis[J]. Hepatobiliary Surgery Nutrition, 2022, 11(6): 913-916.

培门冬酶注射液致急性重症胰腺炎1例分析

One case of acute severe pancreatitis caused by pegaspargase and its etiology

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	魏曼莉, 吕林艳, 郑志远, 尹纪业, 麦志雄. 血栓通注射液临床前遗传毒性研究[J]. 中国药物警戒, 2024, 21(9): 1014-1018.
[2]	孟康康, 夏玉坤. 昂丹司琼制剂安全性风险分析[J]. 中国药物警戒, 2024, 21(9): 1034-1038.
[3]	吴凡, 付林杰, 祝赫, 徐梦艳. 基于美国FAERS和日本JADER数据库的内皮素受体拮抗剂不良事件信号分析[J]. 中国药物警戒, 2024, 21(9): 1056-1063.
[4]	卢靖, 喻珊珊, 童菲, 林卓慧, 宋路瑶. 达格列净片致严重便秘1例分析[J]. 中国药物警戒, 2024, 21(9): 1071-1074.
[5]	郑丽, 张凯华, 孙雪林. 小细胞肺癌治疗新药Tarlatamab药理作用及临床评价[J]. 中国药物警戒, 2024, 21(9): 1078-1080.
[6]	王岩, 滕晶晶, 杨同金, 夏新, 喻丹丹, 占海兵, 杨文明. 智脑胶囊长期毒性研究[J]. 中国药物警戒, 2024, 21(8): 878-883.
[7]	刘毅, 刘晓强, 姚晓, 李选堂, 郭贤辉, 耿颖, 裴宇盛. 溴己新注射剂临床配伍用药研究[J]. 中国药物警戒, 2024, 21(8): 884-887.
[8]	孙一鑫, 聂晓璐, 王晓玲, 郭鹏. 国内外基于真实世界数据的药品上市后安全性主动监测系统对比分析[J]. 中国药物警戒, 2024, 21(8): 892-899.
[9]	魏芬芳, 吴文宇, 李丽敏, 唐碧雨, 吴建茹. 国外药品获益-风险评价方法概述与启示[J]. 中国药物警戒, 2024, 21(8): 900-905.
[10]	刘倩, 李博, 疏欣扬. 蓝芩口服液联合抗菌药物治疗急性扁桃体炎有效性与安全性的系统评价与Meta分析[J]. 中国药物警戒, 2024, 21(8): 916-920.
[11]	王玉玺, 张宗林, 王颖丽, 陈亚飞, 李俊生, 霍艳飞, 谢彦军, 刘文启. 560例脉络舒通丸不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 921-924.
[12]	赵俊, 董丽, 王洋, 梁瑜, 杨雪, 李恩泽. 艾司洛尔不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 925-930.
[13]	张乾, 恽渊, 何恋. 1例利培酮致高泌乳素血症患者的药学监护[J]. 中国药物警戒, 2024, 21(8): 936-938.
[14]	晁滢, 张学梅, 张成健, 王贝. 注射用头孢曲松钠致儿童输尿管结石及胆囊结石1例分析[J]. 中国药物警戒, 2024, 21(8): 943-945.
[15]	郭海嬿, 何波, 闫鸿丽, 杨雪婷. 稳心颗粒致持续性呃逆1例分析[J]. 中国药物警戒, 2024, 21(8): 946-948.